ClinicalTrials.gg
Not yet recruitingNCT06584058Updated Sep 4, 2024

HPP737 Substance Balance Study in Human

An interventional study of HPP737 in Psoriasis, sponsored by Newsoara Biopharma Co., Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Newsoara Biopharma Co., Ltd. · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
175th of 182
8 · median 171
Started
2024
with 24 others
No phase
20 of 206
7 open now
Primary completion
2025-07
later than 8 of 65 live
Registered
137th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 175th largest by planned enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 20 with no phase, reaches primary completion later than 8 of the 65 other live ones, and was the 137th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

Main research purpose

  1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of [14C]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity;
  2. To identify the main metabolites in the offspring of [14C]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure;
  3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of [14C]HPP737.

Participants will:

  1. Take Investigational product once
  2. Stay in the clinic about 7 days for checkups and tests
  3. Report their symptoms
03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese healthy adult males, aged 18-45 years (including boundary values);
  2. The body weight of the subject is not less than 50kg, and the (BMI) is between 19.0 and 26.0kg/m2 (including the boundary value);
  3. The subject has no sperm donation plan during the trial period and within six months after the completion of the trial, and the subject and his or her partner have no birth plan during the trial period and within six months after the completion of the trial and voluntarily take strict measures (see Appendix 4 for details);
  4. Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the written , and be able to complete the whole process of the trial according to the requirements of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Those who have undergone comprehensive physical examination, vital signs, laboratory examination (blood routine, blood biochemistry, coagulation test, urine routine, infectious disease screening, thyroid function, stool routine + occult blood), chest X-ray (positive position), anal digital examination, abdominal B-ultrasound (liver, bile, pancreas, spleen and kidney), urinary system B-ultrasound, and heart color ultrasound with clinical significance;
  2. During the screening period, any abnormalities determined by the investigators to be , including but not limited to electrocardiograms with machine reading abnormalities: Fridericia's formula (=QT/ (RR\^0.33)) corrected QT interval (QTcF) >450 msec, QRS>110 msec, frequent atrial or ventricular premature beats;
  3. Patients with abnormal color vision, retinitis pigmentosa, macular degeneration, nonarteriotic anterior ischemic optic neuropathy (NAION), or other fundus history deemed unsuitable by the investigators;
  4. Allergic constitution, such as people who are known to be allergic to two or more substances, or have allergic diseases, or have a history of allergy to PDE4 inhibitors or similar drugs or their ;
  5. Habitual constipation or diarrhea, a history of malabsorption syndrome, or a history of severe nausea, vomiting, diarrhea, and constipation within one week before the screening period;
  6. have difficulty swallowing or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy);
  7. Have a history of clinically serious disease or any disease or condition that the investigator believes may affect the test results, including but not limited to a history of digestive, circulatory, respiratory, endocrine, nervous, urinary, or blood, immune, psychiatric, or metabolic diseases;
  8. Previous history of organic heart disease, heart failure, myocardial infarction, angina pectoris, torsional ventricular tachycardia, ventricular tachycardia, QT prolongation syndrome or family history (genetic proof or close relatives at a young age due to sudden cardiac death);
  9. Major surgery or surgical incision not fully healed within 6 months prior to screening; Major surgery includes, but is not limited to, any surgery where there is a significant risk of bleeding, extended period of general anesthesia, or open or significant traumatic injury;
  10. Previous active bleeding (such as peptic ulcer, intracranial hemorrhage, skin ecchymosis, gingival bleeding); History of any medical condition that may increase the risk of bleeding (e.g. tumor bleeding, spontaneous hematoma, eye bleeding, hemoptysis, gastrointestinal bleeding or ulcers, hematuria, reproductive system bleeding, traumatic hematoma/bleeding and recurrent epistaxis/gingival bleeding/subcutaneous or skin bleeding, etc.) within 6 months prior to screening;
  11. Hemorrhoids or perianal disease accompanied by regular/blood in the stool, or positive stool occult blood test during the screening period;
  12. Use of any drug that affects drug metabolism enzymes or transporters (P-gp and BCRP) in the 30 days prior to screening, as detailed in Appendix 5;
  13. Have taken any prescription drugs, over-the-counter drugs, Chinese herbs or food supplements (vitamins, calcium supplements) in the 14 days prior to screening and before dosing;
  14. Those who have taken any clinical trial drug or participated in any other clinical trial (including drug and device clinical trials) within 3 months prior to the screening period;
  15. Those who have lost blood or donated blood (≥400mL) within 3 months before screening, or received blood transfusion or blood components within 1 month, or plan to donate blood within 3 months after the end of this trial;
  16. Smokers who smoked more than 5 cigarettes per day or habitually used nicotine-containing products in the 3 months prior to the screening period, or were unable to stop using any tobacco products during the trial period;
  17. Regular alcohol consumption in the six months prior to screening, i.e. drinking more than 14 units of alcohol per week (1 unit =285mL of beer or 25mL of 40% alcohol spirits or 100mL of wine), or a positive alcohol breath test, or unable to abstain during the test period;
  18. Drug abuse or drug use history, or drug abuse screening positive;
  19. Habitual or excessive (more than 8 cups a day, 1 cup =250mL) consumption of grapefruit juice, tea, coffee and/or caffeinated beverages, and unable to abstain during the trial period;
  20. Those who have special requirements for diet and cannot comply with a unified diet;
  21. Workers who require long-term exposure to radiation, or who have had significant radiation exposure (≥2 chest/abdominal CT, or ≥3 other types of X-rays) in the year prior to administration, or who have participated in radiopharma labeling tests;
  22. Patients with a history of needle fainting and blood fainting, difficulty in blood collection or inability to tolerate venous puncture blood collection;
  23. Those who had been vaccinated within 1 month prior to screening or planned to be vaccinated during the trial period;
  24. Subjects whose compliance is considered poor by the investigator, or who have other factors unsuitable for participation in this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    All healthy subjects

    Drug: HPP737

Interventions

  • DrugHPP737

    \[14C\]HPP737 oral preparation, 20mg(150μCi), once

06

What researchers measure

Primary outcomes

  1. Cmax (peak concentration)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  2. Tmax (peak time)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  3. AUC0-T (area under drug time curve)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  4. AUC0-∞ (area under drug time curve)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  5. t1/2 (elimination half-life)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  6. CL/F (apparent clearance)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  7. Vd/F (apparent volume of distribution)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  8. MRT (mean residence time)

    radiation pharmacokinetic parameter

    Time frame: Up to 12 months

  9. Cumulative drug excretion(Urine)

    Radioactive excretion corresponding to urine samples

    Time frame: Up to 12 months

  10. Cumulative drug excretion(stool)

    Radioactive excretion corresponding to stool samples

    Time frame: Up to 12 months

  11. Major metabolite

    The main metabolites in plasma, urine and fecal samples were identified by liquid chromatography-mass spectrometry (LC-MS), and radioisotope metabolites were analyzed to provide the main biotransformation pathway of HPP737 in human body.

    Time frame: Up to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Jul 2025, 11 months later.

Of 134 interventional studies with no phase under Psoriasis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Sep 4, 2024
StartEst.
Aug 30, 2024
Primary completionEst.
Jul 30, 2025
CompletionEst.
Aug 30, 2025
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06584058
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Aug 30, 2024 (estimated)
Primary completion
Jul 30, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Sep 4, 2024

Study contacts

Jason Chen
Contact
jason.chen@newsoara.com
13681963490
Jie Pan, Master
principal investigator · Second Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HPP737

Start the discussion